Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 11 , ISSUE 4 ( October-December, 2022 ) > List of Articles

EDITORIAL

Managing Acute Exacerbation of Chronic Obstructive Pulmonary Disease: What's New?

R. Adhitiya Raman, Harish Mallapura Maheshwarappa

Citation Information : Raman RA, Maheshwarappa HM. Managing Acute Exacerbation of Chronic Obstructive Pulmonary Disease: What's New?. Indian J Respir Care 2022; 11 (4):287-290.

DOI: 10.4103/ijrc.ijrc_177_22

License: CC BY-NC-SA 4.0

Published Online: 01-12-2022

Copyright Statement:  Copyright © 2022; Indian Journal of Respiratory Care.


Abstract

HTML PDF Share
  1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-88.
  2. Celli BR, Agustí A. COPD: Time to improve its taxonomy? ERJ Open Res 2018;4:00132-2017.
  3. Wedzicha JA, Seemungal TA. COPD exacerbations: Defining their cause and prevention. Lancet 2007;370:786-96.
  4. Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. Am J Health Syst Pharm 2020;77:259-68.
  5. Rosenberg SR, Kalhan R. Recent advances in the management of chronic obstructive pulmonary disease. F1000Res 2017;6:863.
  6. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
  7. Husebø GR, Bakke PS, Aanerud M, Hardie JA, Ueland T, Grønseth R, et al. Predictors of exacerbations in chronic obstructive pulmonary disease-results from the Bergen COPD cohort study. PLoS One 2014;9:e109721.
  8. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
  9. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev 2016;2016:CD011826.
  10. Bardsley G, Pilcher J, McKinstry S, Shirtcliffe P, Berry J, Fingleton J, et al. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: A randomised controlled trial. BMC Pulm Med 2018;18:157.
  11. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7.
  12. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet 1999;354:456-60.
  13. Wedzicha JA, Calverley PM, Albert RK, Anzueto A, Criner GJ, Hurst JR, et al. Prevention of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;50:1602265.
  14. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.
  15. Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): A multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med 2019;7:699-709.
  16. Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003;(2):CD002168.
  17. Fu C, Liu X, Zhu Q, Wu X, Hao S, Xie L, et al. Efficiency of high-flow nasal cannula on pulmonary rehabilitation in COPD patients: A meta-analysis. Biomed Res Int 2020;2020:7097243.
  18. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017;7:CD004104.
  19. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
  20. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
  21. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8.
  22. Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B. Profiling the bronchodilator effects of the novel ultra-long-acting ß2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011;5:345-57.
  23. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med 2013;1:524-33.
  24. Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011;12:55.
  25. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J 2012;40:830-6.
  26. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: A randomised, placebo-controlled study. Eur Respir J 2014;43:72-81.
  27. LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, et al. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: The GEM1 study. Int J Chron Obstruct Pulmon Dis 2016;11:1233-43.
  28. Bateman ED, Chapman KR, Singh D, D'Urzo AD, Molins E, Leselbaum A, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: Pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res 2015;16:92.
  29. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: Results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472-86.
  30. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: A randomized, controlled study. Chest 2014;145:981-91.
  31. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34.
  32. Lai CC, Chen CH, Lin CY, Wang CY, Wang YH. The effects of single inhaler triple therapy vs. single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis 2019;14:1539-48.
  33. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;383:35-48.
  34. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD 2022 Report; 2022.
  35. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet 2015;385:857-66.
  36. Rabe KF, Calverley PM, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J 2017;50:1700158.
  37. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr., Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
  38. Gavish R, Levy A, Dekel OK, Karp E, Maimon N. The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. Chest 2015;148:375-81.
  39. Deslée G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, et al. Lung volume reduction coil treatment vs. usual care in patients with severe emphysema: The REVOLENS Randomized Clinical Trial. JAMA 2016;315:175-84.
  40. Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, et al. Effect of endobronchial coils vs. usual care on exercise tolerance in patients with severe emphysema: The RENEW Randomized Clinical Trial. JAMA 2016;315:2178-89.
  41. Davey C, Zoumot Z, Jordan S, McNulty WH, Carr DH, Hind MD, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): A randomised controlled trial. Lancet 2015;386:1066-73.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.